Alnylam Pharmaceuticals
ALNY
#378
Rank
$60.52 B
Marketcap
$458.12
Share price
-1.55%
Change (1 day)
78.77%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2025 (TTM): $0.09000

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is $0.09000. In 2023 the company made an earnings per share (EPS) of -$3.53 an increase over its 2022 EPS that were of -$9.29.

EPS history for Alnylam Pharmaceuticals from 2012 to 2025

Annual EPS

Year EPS Change
2025 (TTM)$0.09000
2023-$3.53-62%
2022-$9.2929.03%
2021-$7.20-3.36%
2020-$7.45-8.48%
2019-$8.147.67%
2018-$7.5639.74%
2017-$5.4112.94%
2016-$4.7938.84%
2015-$3.45-32.88%
2014-$5.14259.44%
2013-$1.43-31.25%
2012-$2.08

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Arrowhead Pharmaceuticals
ARWR
-$1.25-1,488.89%๐Ÿ‡บ๐Ÿ‡ธ USA
Regeneron Pharmaceuticals
REGN
$43.44 48,166.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Sarepta Therapeutics
SRPT
-$2.74-3,144.44%๐Ÿ‡บ๐Ÿ‡ธ USA
OPKO Health
OPK
-$0.24-366.67%๐Ÿ‡บ๐Ÿ‡ธ USA
Regulus Therapeutics
RGLS
-$0.73-911.11%๐Ÿ‡บ๐Ÿ‡ธ USA
Novartis
NVS
$7.36 8,077.78%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Sanofi
SNY
$3.71 4,017.43%๐Ÿ‡ซ๐Ÿ‡ท France
Teva Pharmaceutical Industries
TEVA
$0.63 600.00%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel